EWS
VRTX icon

Eagle Wealth Strategies’s Vertex Pharmaceuticals VRTX Stock Holding History

Eagle Wealth Strategies’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-473
Closed -$211K – 111
2025
Q2 		$211K Sell
473
-71
-13% -$32.7K 0.12% 95
2025
Q1 		$264K Sell
544
-21
-4% -$9.79K 0.16% 72
2024
Q4 		$228K Buy
565
+10
+2% +$4.63K 0.16% 91
2024
Q3 		$258K Sell
555
-2
-0.4% -$961 0.19% 90
2024
Q2 		$261K Sell
557
-407
-42% -$177K 0.21% 74
2024
Q1 		$405K Sell
964
-55
-5% -$23.3K 0.33% 49
2023
Q4 		$415K Buy
+1,019
New +$376K 0.25% 49

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Eagle Wealth Strategies's VRTX Position: Q3 2025 in Review

Eagle Wealth Strategies sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 473 shares — an estimated $211K sold.

Eagle Wealth Strategies first reported a position in VRTX in Q4 2023 and held it in 7 quarters. The position peaked at $415K in Q4 2023. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Eagle Wealth Strategies reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Eagle Wealth Strategies sold 473 Vertex Pharmaceuticals shares in Q3 2025, an estimated $211K.
  • Eagle Wealth Strategies first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • Eagle Wealth Strategies's Vertex Pharmaceuticals position peaked at $415K in Q4 2023.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Eagle Wealth Strategies's 13F filing for Q3 2025, filed 7 Nov 2025.